Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALOR
NCT05714085Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2023
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial of Vericiguat oral suspension (Formulation 4) in heart failure (HF) (3 arms), sponsored by Merck & Co. Primary endpoints: Change from baseline in N-terminal pro-brain natriuretic peptide at 16 weeks, Percentage of participants with one or more adverse events at 8 years and 1 more. Started May 2023; status: recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05714085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05714085.